InvestorsHub Logo
Followers 861
Posts 28265
Boards Moderated 1
Alias Born 03/16/2014

Re: None

Friday, 10/16/2020 12:45:18 PM

Friday, October 16, 2020 12:45:18 PM

Post# of 30145
I’ve recently communicated with Validcare and their liver safety study is going very well

They are closing in on 1000 participants and expect to conclude the study within the next few weeks

Before Covid-19 hit, they had planned on starting the study in March and ending it in June

So everything got pushed back 4-5 months due to the pandemic

The FDA already knows that CBD Isolate at low doses (under 70 mg/day) is safe to ingest, due to all the research that GW Pharma has performed

So the new information this study will provide the FDA is whether adding other cannabinoids to CBD will be harmful to the liver

I haven’t spoken with anybody who believes that the low doses regularly taken by CBD users (10-50 mg) cause any issues with liver function

But it will be very good to finally have evidence from over a dozen CBD products in a well-designed study


Sleek

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.